Christopher Earnhardt, MD
Family Medicine · Minden, LANPI 1699762948
Payments from drug & device makers
Across 359 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$550
- Pfizer$520
- GSK$492
- AstraZeneca$456
- Astellas Pharma US Inc$405
- plus $1K from 27 others
What the payments were for
- Food & beverage$5,08196%
- Education$1994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 124 | $1,522 |
| Novo Nordisk | 36 | $550 |
| Pfizer | 35 | $520 |
| GSK | 29 | $492 |
| AstraZeneca | 26 | $456 |
| Astellas Pharma US Inc | 20 | $405 |
| Sunovion Pharmaceuticals Inc. | 17 | $181 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $146 |
| Merck | 8 | $119 |
| Amgen | 6 | $102 |
| Lilly USA, LLC | 6 | $99 |
| Novartis | 6 | $89 |
| Mylan Specialty L.p. | 3 | $52 |
| Eisai Inc. | 3 | $50 |
| Exact Sciences | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Abbott | 2 | $35 |
| Inogen, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Shield Therapeutics Inc | 2 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Abiomed | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$5,280 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 445 | $567,330 |
| OzempicSemaglutide | 388 | $490,008 |
| FarxigaDapagliflozin Propanediol | 439 | $412,261 |
| JardianceEmpagliflozin | 346 | $331,846 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $256,600 |
| EliquisApixaban | 292 | $234,780 |
| TrulicityDulaglutide | 73 | $115,095 |
| JanuviaSitagliptin Phosphate | 110 | $102,455 |
| MyrbetriqMirabegron | 149 | $88,218 |
| XareltoRivaroxaban | 101 | $86,122 |
| LinzessLinaclotide | 87 | $79,432 |
| Tresiba Flextouch U-200Insulin Degludec | 64 | $76,211 |
| EntrestoSacubitril/Valsartan | 70 | $68,450 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $64,624 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 127 | $40,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $99 | $682,425518 claims |
| Novo NordiskOzempic | $550 | $490,008388 claims |
| AstraZenecaFarxiga, Brilinta | $456 | $427,653456 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $14 | $365,505384 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $492 | $300,272484 claims |
| PfizerEliquis, Abrysvo | $520 | $275,519419 claims |
| MerckJanuvia, Janumet Xr, Janumet | $119 | $146,118176 claims |
| AbbVieLinzess, Ubrelvy | $1,522 | $103,865107 claims |
| Astellas Pharma US IncMyrbetriq | $405 | $88,218149 claims |
| Johnson & JohnsonXarelto | $15 | $86,122101 claims |
| NovartisEntresto | $89 | $68,45070 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $19 | $7,82815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Minden
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.